Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25

January 30, 2025

Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, 2025. Despite a significant drop in net profit, revenue and EBITDA have grown. Increased biosimilar market share and strategic approvals are expected to drive future growth.

More To Explore

Mind Over Money: From pitch to boardroom: how soccer shapes the leadership style of DCB Bank CEO Praveen Kutty

Praveen Kutty leads DCB Bank. He uses soccer principles in his management style. Kutty emphasizes teamwork and strategic thinking. He believes in identifying individual strengths.

May 31, 2025

Balanced advantage vs. Multi Asset Allocation Mutual Funds: Which should investors choose?

Balanced Advantage Funds and Multi Asset Allocation Funds offer different risk-return profiles. Balanced Advantage Funds dynamically shift between equity and debt. Multi Asset Funds invest

May 31, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003